SAN MATEO, CA -- (MARKET WIRE) -- April 26, 2007 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has acquired the exclusive rights in the United States and Canada to develop and commercialize RP101, a clinical-stage compound for the treatment of cancer. SciClone acquired the rights from Resistys, Inc., a wholly owned subsidiary of Avantogen Oncology, Inc. In a previous phase 1 clinical trial evaluating RP101 in combination with gemcitabine, the current standard of care, to treat late-stage pancreatic cancer patients, the median survival for the RP101 treated group was 9.3 months, compared to the historical control of approximately 6 months for patients treated with gemcitabine alone.
